EP2398900A4 - Populations monocytaires isolées et applications thérapeutiques associées - Google Patents

Populations monocytaires isolées et applications thérapeutiques associées

Info

Publication number: EP2398900A4
Authority: EP; European Patent Office
Prior art keywords: therapeutic applications; corresponding therapeutic; monocyte populations; isolated monocyte; isolated
Prior art date: 2009-02-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP10744061A

Other languages

German (de)

English (en)

Other versions

EP2398900A1 (fr

Inventor

Martin Friedlander

Matthew R Ritter

Stacey K Moreno

Mohammad A El-Kalay

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Scripps Research Institute

Original Assignee

Scripps Research Institute

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-20

Filing date

2010-02-19

Publication date

2012-08-22

2010-02-19 Application filed by Scripps Research Institute filed Critical Scripps Research Institute

2011-12-28 Publication of EP2398900A1 publication Critical patent/EP2398900A1/fr

2012-08-22 Publication of EP2398900A4 publication Critical patent/EP2398900A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/051—Lipid A (MPA, MPL)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/042—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1497—Particle shape

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Ophthalmology & Optometry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP10744061A 2009-02-20 2010-02-19 Populations monocytaires isolées et applications thérapeutiques associées Withdrawn EP2398900A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20817309P	2009-02-20	2009-02-20
US28324409P	2009-11-30	2009-11-30
PCT/US2010/000477 WO2010096177A1 (fr)	2009-02-20	2010-02-19	Populations monocytaires isolées et applications thérapeutiques associées

Publications (2)

Publication Number	Publication Date
EP2398900A1 EP2398900A1 (fr)	2011-12-28
EP2398900A4 true EP2398900A4 (fr)	2012-08-22

Family

ID=42634163

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP10744061A Withdrawn EP2398900A4 (fr)	2009-02-20	2010-02-19	Populations monocytaires isolées et applications thérapeutiques associées

Country Status (11)

Country	Link
EP (1)	EP2398900A4 (fr)
JP (1)	JP2012518407A (fr)
KR (1)	KR20110123778A (fr)
CN (1)	CN102317446A (fr)
AU (1)	AU2010216374A1 (fr)
BR (1)	BRPI1008392A2 (fr)
CA (1)	CA2752679A1 (fr)
EA (1)	EA201190109A1 (fr)
MX (1)	MX2011008826A (fr)
WO (1)	WO2010096177A1 (fr)
ZA (1)	ZA201105869B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2999479B1 (fr) *	2013-05-22	2021-01-06	Yeda Research and Development Co., Ltd.	Sous-population de monocytes humains pour le traitement de maladies et de troubles oculaires
KR101668462B1 (ko) *	2015-02-26	2016-10-24	충북대학교 산학협력단	혈액성분을 유효성분으로 포함하는 녹내장의 예방 또는 치료용 약제학적 조성물
FR3084463B1 (fr) *	2018-07-30	2023-04-21	Francais Du Sang Ets	Procede d'analyse des plaquettes d'un echantillon sanguin
WO2023102431A1 (fr) *	2021-11-30	2023-06-08	Ohio State Innovation Foundation	Cellules modifiées et leurs utilisations
CN114441419B (zh) *	2022-01-29	2022-11-22	杭州翔宇医学检验实验室有限公司	流式圈门方法及应用
CN117949371A (zh) *	2024-01-30	2024-04-30	广东省妇幼保健院（广东省妇产医院、广东省儿童医院）	Cd3+cd4+cd38+细胞在早产儿视网膜病变诊断中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006031467A2 (fr) *	2002-07-25	2006-03-23	The Scripps Research Institute	Cellules souches hematopoietiques de lignees negatives isolees et methodes de traitement associees
WO2008001380A2 (fr) *	2006-06-28	2008-01-03	Yeda Research And Development Co. Ltd.	Méthode de traitement de la dégénérescence maculaire liée à l'âge

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005083061A1 (fr) *	2004-02-11	2005-09-09	Aldagen, Inc.	Populations de cellules souches et procédés d'utilisation
US20070231306A1 (en) *	2005-02-24	2007-10-04	The Scripps Research Institute	Isolated myeloid-like cell populations and methods of treatment therewith

2010
- 2010-02-19 EA EA201190109A patent/EA201190109A1/ru unknown
- 2010-02-19 CN CN2010800079738A patent/CN102317446A/zh active Pending
- 2010-02-19 WO PCT/US2010/000477 patent/WO2010096177A1/fr not_active Ceased
- 2010-02-19 KR KR1020117021989A patent/KR20110123778A/ko not_active Withdrawn
- 2010-02-19 AU AU2010216374A patent/AU2010216374A1/en not_active Abandoned
- 2010-02-19 EP EP10744061A patent/EP2398900A4/fr not_active Withdrawn
- 2010-02-19 MX MX2011008826A patent/MX2011008826A/es not_active Application Discontinuation
- 2010-02-19 JP JP2011551065A patent/JP2012518407A/ja not_active Withdrawn
- 2010-02-19 BR BRPI1008392-8A patent/BRPI1008392A2/pt not_active IP Right Cessation
- 2010-02-19 CA CA2752679A patent/CA2752679A1/fr not_active Abandoned
2011
- 2011-08-11 ZA ZA2011/05869A patent/ZA201105869B/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006031467A2 (fr) *	2002-07-25	2006-03-23	The Scripps Research Institute	Cellules souches hematopoietiques de lignees negatives isolees et methodes de traitement associees
WO2008001380A2 (fr) *	2006-06-28	2008-01-03	Yeda Research And Development Co. Ltd.	Méthode de traitement de la dégénérescence maculaire liée à l'âge

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGUILAR EDITH ET AL: "OCULAR MODELS OF ANGIOGENESIS", METHODS IN ENZYMOLOGY ELSEVIER ACADEMIC PRESS INC, 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SERIES : METHODS IN ENZYMOLOGY (ISSN 0076-6879(PRINT)), 2008, pages 115 - 158, XP009160775 *
HAZIOT A ET AL: "SOLUBLE CD14 INHIBITS THE ACTIVATION OF MONOCYTES INDUCED BY LPS", JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT, A.R. LISS, NEW YORK, NY, US, 21 February 1992 (1992-02-21), pages 163, XP000775642, ISSN: 0733-1959 *
See also references of WO2010096177A1 *
SUMEGI ET AL: "Glucocorticosteroid therapy decreases CD14-expression and CD14-mediated LPS-binding and activation of monocytes in patients suffering from systemic lupus erythematosus", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 117, no. 3, 1 December 2005 (2005-12-01), pages 271 - 279, XP005226349, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2005.09.002 *

Also Published As

Publication number	Publication date
CA2752679A1 (fr)	2010-08-26
WO2010096177A1 (fr)	2010-08-26
EA201190109A1 (ru)	2012-07-30
MX2011008826A (es)	2011-11-02
CN102317446A (zh)	2012-01-11
ZA201105869B (en)	2012-10-31
AU2010216374A1 (en)	2011-08-18
BRPI1008392A2 (pt)	2015-08-25
EP2398900A1 (fr)	2011-12-28
KR20110123778A (ko)	2011-11-15
JP2012518407A (ja)	2012-08-16

Publication	Publication Date	Title
HRP20160737T1 (hr)	2016-07-15	Anti-her3-protutijela i njihove uporabe
HRP20181493T1 (hr)	2018-11-16	Konjugati epsilon-polilizin i njihova primjena
EP2358730A4 (fr)	2013-04-03	Rébaudioside d hautement pur, et applications correspondantes
EP2347147A4 (fr)	2012-09-12	Ensembles tournants, mécanismes tournants et applications associées
EP2515946A4 (fr)	2015-10-07	Nanoconjugués et compositions de nanoconjugués
ITMI20101577A1 (it)	2011-03-04	Microsistema
EP2475287A4 (fr)	2014-04-16	Siège pour enfant
EP2441646A4 (fr)	2012-12-05	Support et poussette pour bébé
BRPI1004907A2 (pt)	2016-08-09	unidade principal e unidade subordinada
HRP20160579T1 (hr)	2016-07-29	Spoj indola i njegova farmaceutska upotreba
EP2547373A4 (fr)	2014-12-31	Nanotubes et compositions associées
EP3964184C0 (fr)	2024-11-27	Vêtements de compression et systèmes de vêtements de compression
IL225607A0 (en)	2013-06-27	Heteroaryls and uses thereof
BR112012007861A2 (pt)	2019-09-24	dispositivos médicos e suas bombas
UA20209S (uk)	2010-04-12	Крісло гіпертермотерапевтичне
EP2408153A4 (fr)	2015-06-10	Premier serveur relais et second serveur relais
DK2252688T3 (da)	2017-11-13	Syntetiske phosphodiester-oligonukleotider og terapeutiske anvendelser deraf
EP2398900A4 (fr)	2012-08-22	Populations monocytaires isolées et applications thérapeutiques associées
EP2618829A4 (fr)	2014-12-31	Applications thérapeutiques de la smad7
FI20090218A0 (fi)	2009-05-29	Bassokaiuttimen rakenne
DE11786796T8 (de)	2013-04-25	Antigenpeptid und verwendung davon
EP2227485A4 (fr)	2011-09-21	Gène de résistance et ses utilisations
EP2529013A4 (fr)	2013-12-11	Nouvelle -glucosidase et utilisations de celle-ci
EP2508459A4 (fr)	2014-12-17	Câble pour ascenseurs, et dispositif d'ascenseur
FR2965717B1 (fr)	2012-11-30	Fauteuil roulant

Legal Events

Date	Code	Title	Description
2011-11-25	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2011-12-28	17P	Request for examination filed	Effective date: 20110830
2011-12-28	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2012-01-11	RIN1	Information on inventor provided before grant (corrected)	Inventor name: RITTER, MATTHEW, R. Inventor name: FRIEDLANDER, MARTIN Inventor name: MORENO, STACEY, K. Inventor name: EL-KALAY, MOHAMMAD, A.
2012-05-30	DAX	Request for extension of the european patent (deleted)
2012-08-22	A4	Supplementary search report drawn up and despatched	Effective date: 20120719
2012-08-22	RIC1	Information provided on ipc code assigned before grant	Ipc: A01N 63/02 20060101ALI20120713BHEP Ipc: C12N 5/0786 20100101AFI20120713BHEP
2012-11-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2012-12-26	18W	Application withdrawn	Effective date: 20121121